Compare Gilead Sciences, Inc. (GILD) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs 22nd Century Group Inc — how do they compare? Gilead Sciences, Inc. trades at $135.46 (market cap $163.51B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Gilead Sciences, Inc. is far larger — about 107572.4× 22nd Century Group Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| GILD | XXII | |
|---|---|---|
Market Cap | $163.51B | $1.52M |
Sector | Health | Technology |
52-Week High | $155.80 | $1.47K |
52-Week Low | $108.22 | $3.90 |
Enterprise Value | $178.05B | -$6.71M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
22nd Century Group (XXII) trades at $4.33, up 3.34% on the day, following a recent 20:1 reverse stock split. The stock shows a bearish technical signal with support at $4 and resistance at $5. Fundamentally, the company continues to operate at a loss with negative gross and net profit margins, though revenue reached $7.05M in 2025. Recent news highlights aggressive expansion of its VLN reduced-nicotine cigarette brand into California and New York markets.
The outlook remains speculative with significant execution risk. While analyst consensus is strongly bullish (75% buy ratings), the company must demonstrate a path to profitability through its VLN product expansion. Key risks include persistent cash burn, competitive tobacco market pressures, and regulatory uncertainty. The stock represents a high-risk, high-potential turnaround play dependent on commercial success of its reduced-nicotine platform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
